HC Wainwright Increases Earnings Estimates for Humacyte

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Humacyte in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.37) for the year, up from their prior estimate of ($0.50). The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte’s FY2027 earnings at ($0.27) EPS, FY2028 earnings at ($0.06) EPS, FY2029 earnings at $0.10 EPS and FY2030 earnings at $0.38 EPS.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. The firm had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $1.35 million.

Other analysts have also issued research reports about the company. Wall Street Zen lowered Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Friday, March 27th. BTIG Research reduced their price target on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Finally, Benchmark dropped their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.71.

Humacyte Stock Performance

Shares of HUMA stock opened at $0.59 on Thursday. The firm has a market cap of $110.85 million, a price-to-earnings ratio of -2.96 and a beta of 2.11. The company’s 50 day moving average is $1.02 and its 200 day moving average is $1.26. The company has a quick ratio of 0.90, a current ratio of 3.69 and a debt-to-equity ratio of 20.08. Humacyte has a 52-week low of $0.55 and a 52-week high of $2.93.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently made changes to their positions in HUMA. Geode Capital Management LLC grew its stake in Humacyte by 33.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after buying an additional 738,142 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Humacyte by 31.3% in the second quarter. JPMorgan Chase & Co. now owns 70,067 shares of the company’s stock valued at $146,000 after buying an additional 16,702 shares during the last quarter. Rhumbline Advisers raised its stake in Humacyte by 51.1% in the second quarter. Rhumbline Advisers now owns 177,623 shares of the company’s stock valued at $371,000 after buying an additional 60,059 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Humacyte in the second quarter worth about $28,000. Finally, XTX Topco Ltd boosted its holdings in Humacyte by 440.7% in the second quarter. XTX Topco Ltd now owns 290,888 shares of the company’s stock worth $608,000 after acquiring an additional 237,091 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.